Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
NCT00056381
Last updated date
ABOUT THIS STUDY
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of
fungal infections. This study is evaluating anidulafungin in children and adolescents who
have fever and a low white blood cell count (neutropenia).
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neutropenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
2-17 years
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
NeutropeniaA Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children
NCT00174473
ALL GENDERS
2 Years+
years
MULTIPLE SITES
NeutropeniaSafety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
NCT00056381
- King of Prussia, Pennsylvania
ALL GENDERS
2 Years+
years
MULTIPLE SITES
NeutropeniaA Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants
NCT02629289
- Adelaide, South Australia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||
|---|---|---|---|
| Brief Title ICMJE | Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 | ||
| Official Title ICMJE | Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia | ||
| Brief Summary | Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia). | ||
| Detailed Description | Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi. | ||
| Study Type ICMJE | Interventional | ||
| Study Phase ICMJE | Phase 1 Phase 2 | ||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||
| Condition ICMJE | Neutropenia | ||
| Intervention ICMJE | Drug: Anidulafungin | ||
| Study Arms ICMJE | Not Provided | ||
| Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||
| Recruitment Information | |||
| Recruitment Status ICMJE | Completed | ||
| Actual Enrollment ICMJE | 25 | ||
| Original Enrollment ICMJE | 24 | ||
| Actual Study Completion Date ICMJE | June 2004 | ||
| Primary Completion Date | Not Provided | ||
| Eligibility Criteria ICMJE |
| ||
| Sex/Gender ICMJE |
| ||
| Ages ICMJE | 2 Years to 17 Years (Child) | ||
| Accepts Healthy Volunteers ICMJE | No | ||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
| Listed Location Countries ICMJE | United States | ||
| Removed Location Countries | |||
| Administrative Information | |||
| NCT Number ICMJE | NCT00056381 | ||
| Other Study ID Numbers ICMJE | VER002-12 A8851005 | ||
| Has Data Monitoring Committee | Not Provided | ||
| U.S. FDA-regulated Product | Not Provided | ||
| IPD Sharing Statement ICMJE | Not Provided | ||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | ||
| Study Sponsor ICMJE | Pfizer | ||
| Collaborators ICMJE | Vicuron Pharmaceuticals | ||
| Investigators ICMJE | Not Provided | ||
| PRS Account | Pfizer | ||
| Verification Date | October 2008 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||